Michael T. Sandholzer

Michael T. Sandholzer

Auto-generated profile, based on publicly available information

Michael T. Sandholzer

Department of Biomedicine, University Hospital Basel and University of Basel, Switzerland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2024 in Cellular & Molecular Immunology
Verified
Journal Article
Open access
PDF file
RWRonja Wieboldt
Ronja Wieboldt
MSMichael Sandholzer
Michael Sandholzer
ECEmanuele Carlini
Emanuele Carlini
CLChia-Wei Lin
Chia-Wei Lin
ABAnastasiya Börsch
Anastasiya Börsch
NMNatalia Rodrigues Mantuano
Natalia Rodrigues Mantuano
The overexpression of sialic acids on glycans, called hypersialylation, is a common alteration found in cancer cells. Sialylated glycans can enhance immune evasion by interacting with sialic acid-binding immunoglobulin-like lectin (Siglec) receptors on tumor-infiltrating immune cells. Here, we investigated the effect of sialylated glycans and their interaction with Siglec receptors on myeloid-derived suppressor cells (MDSCs). We found that MDSCs derived from the blood of lung cancer patients and tumor-bearing mice strongly express inhibitory Siglec receptors and are highly sialylated. In murine cancer models of emergency myelopoiesis, Siglec-E knockout in myeloid cells resulted in prolonged survival and increased tumor infiltration of activated T cells. Targeting suppressive myeloid cells by blocking Siglec receptors or desialylation strongly reduced their suppressive potential. We further identified CCL2 as a mediator involved in T-cell suppression upon interaction between sialoglycans and Siglec receptors on MDSCs. Our results demonstrated that sialylated glycans inhibit anticancer immunity by modulating CCL2 expression.

9 June 2020 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
CPChristian Pellegrino
Christian Pellegrino
NFNicholas Favalli
Nicholas Favalli
MSMichael Sandholzer
Michael Sandholzer
LVLaura Volta
Laura Volta
GBGabriele Bassi
Gabriele Bassi
DNDario Neri
Dario Neri

17 April 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
DKDavid König
David König
MSMichael T. Sandholzer
Michael T. Sandholzer
SUSarp Uzun
Sarp Uzun
AZAndreas Zingg
Andreas Zingg
RRReto Ritschard
Reto Ritschard
HLHeinz Läubli
Heinz Läubli
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is effective in patients with melanoma, although long-term responses seem restricted in patients who have complete remissions. Many patients develop secondary resistance to TIL-ACT but the involved mechanisms are unclear. In this study, we describe a case of secondary resistance to TIL-ACT possibly due to intratumoral heterogeneity and selection of a resistant tumor cell clone by the transferred T cells. To the best our knowledge, this is the first case of clonal selection of a pre-existing nondominant tumor cell clone; this report demonstrates the mechanism involved in secondary resistance to TIL-ACT that can potentially change current clinical practice because it advocates for T-cell collection from multiple tumor sites and analysis of tumor heterogeneity before treatment with TIL-ACT.

17 September 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
IFIrene Fusi
Irene Fusi
CSClara Serger
Clara Serger
PHPetra Herzig
Petra Herzig
MGMarkus Germann
Markus Germann
MSMichael T. Sandholzer
Michael T. Sandholzer
AZAlfred Zippelius
Alfred Zippelius
Antibody-cytokine fusion proteins are being developed as next-generation cancer immunotherapies, aiming to deliver activation signals to targeted immune populations. Among these, PD1-IL2v—an engineered interleukin-2 variant (IL-2v) lacking CD25 binding, fused to a high-affinity programmed cell death protein 1 (PD-1) blocking antibody—has shown promising results in murine tumor models. Here, using human model systems, we show that PD1-IL2v elicits a multifaceted antitumor T cell response by targeting both CD8 + and conventional CD4 + T (T conv ) cells. Single-cell RNA sequencing (scRNAseq) on a lung cancer patient–derived tumor fragment (PDTF) platform revealed that PD1-IL2v drives the expansion of proliferative, cytotoxic CD8 + T cells exhibiting features of tumor reactivity. This was accompanied by up-regulation of CXCR6, enhancing their migratory capacity. In T conv cells, PD1-IL2v up-regulated CXCL13 expression and promoted a T follicular helper/T helper 1 (T FH /T H 1)–like transcriptional program associated with anti-PD1 responsiveness. Our findings provide mechanistic insights into the effects of IL-2v–targeted delivery to PD-1 + cells within human tumors, supporting the clinical development of next-generation immunocytokines.

25 September 2025 in bioRxiv
Verified
Preprint
Open access
MSMichael T. Sandholzer
Michael T. Sandholzer
CSClara Serger
Clara Serger
ALAlessia G. Liner
Alessia G. Liner
SUSarp Uzun
Sarp Uzun
DKDavid König
David König
HLHeinz Läubli
Heinz Läubli
Adoptive cell therapy (ACT) with expanded autologous tumor-infiltrating lymphocytes (TILs) can induce durable responses in metastatic melanoma, yet many patients relapse. We profiled tumor-reactive T cell dynamics during TIL therapy using single-cell RNA and TCR sequencing from seven patients to elucidate underlying reasons. We found that tumor-reactive T cells preferentially expanded early during ex vivo TIL culture, transitioning from exhausted to reinvigorated effector states. Particularly, CD8 + exhausted T cells (Tex) and CD4 + follicular helper T cell (Tfh), but not CD4 + Tex, were efficiently reinvigorated. Further, we resolved the heterogeneity of tumor-reactive CD8 + and CD4 + subsets, defining unique signatures for their identification during TIL expansion. In addition, non-responders (NRs) exhibit increased levels of Type 17 T cells in TIL products, suggesting a potential association with resistance to therapy. After transfer, tumor-reactive clones rapidly extravasated and established a stem-like reservoir. However, in NRs, CD4 + regulatory T cells (Tregs) expanded de novo and tumor-reactive CD8 + T cells reacquired exhaustion markers, limiting their functionality. By contrast, responders (Rs) retained a pool of less differentiated, stem-like cells. Collectively, these data provide a comprehensive analysis of T cell fates during TIL-ACT providing the basis for new approaches to enhance therapeutic strategies.

5 June 2026 in Science Immunology
Verified
Journal Article
Closed access
CSClara Serger
Clara Serger
LRLucas Rebuffet
Lucas Rebuffet
MSMichael T. Sandholzer
Michael T. Sandholzer
WRWiebke Rackwitz
Wiebke Rackwitz
IFIrene Fusi
Irene Fusi
AZAlfred Zippelius
Alfred Zippelius
Natural killer (NK) cell–targeting immunotherapies are emerging, yet the differentiation and functional states of tumor-infiltrating NK cells remain poorly understood. Using matched single-nucleus RNA and ATAC sequencing of samples from patients with non–small cell lung cancer (NSCLC), we resolved the transcriptional and epigenetic landscape of intratumoral NK cells. We identified two tumor-associated NK (taNK) cell subsets marked by expression of ITGAE (CD103) and ITGA1 (CD49a) that display features of tissue residency and dysfunction while preserving cytotoxic function. Trajectory and regulon analyses revealed an inflammation-driven transition from early granzyme K ( GZMK ) + NK cells toward an ENTPD1 + (CD39 + ) effector state characterized by interferon-stimulated gene (ISG) programs. Functional profiling established CD39 + taNK cells as the dominant cytotoxic NK cell population with superior killing capacity that was further potentiated by NKG2A blockade. This study offers mechanistic insights into NK cell differentiation in NSCLC and establishes CD39 + taNK cells as a targetable effector population for immunotherapy.